Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
negativerap-celzola-celNegative
AI Analysis
Summary
Novartis halted development of rap-cel across multiple indications and Bristol Myers voluntarily paused its zola-cel program due to safety concerns and side effects observed during testing of these CAR-T therapies.
Outcome Details
Development halted and program paused due to safety concerns and observed side effects
Importance:8/10
Sentiment:
-0.90
CAR-Tsafety concernstrial haltautoimmuneadverse events
Read the original article
Published by BioPharma Dive on August 31, 2026 9:38 PM